کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3164504 1198799 2011 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Clinical presentation and management of mTOR inhibitor-associated stomatitis
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی دندانپزشکی، جراحی دهان و پزشکی
پیش نمایش صفحه اول مقاله
Clinical presentation and management of mTOR inhibitor-associated stomatitis
چکیده انگلیسی

SummaryAnti-cancer agents that inhibit the mTOR pathway are associated with a number of unique toxicities, with one of the most significant and potentially dose-limiting being stomatitis. The objective of this study was to report the clinical features and management outcomes of a series of cancer patients who developed painful mTOR inhibitor-associated stomatitis (mIAS). Seventeen cancer patients developed mIAS while being treated with everolimus- or ridaforolimus-containing protocols at the Dana-Farber Cancer Institute and were referred to the oral medicine clinic for evaluation and management. Clinical characteristics, toxicity management, and outcomes were summarized. In addition, the frequency and rationale for dose reductions and therapy discontinuation were assessed. The median duration of mTOR inhibitor therapy was 80 days (range 9–187 days). The median time to development of mouth ulcers was 10 days (range 4–25 days). Five patients required protocol-directed dose reductions due to grades 2 and 3 stomatitis and one patient discontinued cancer treatment due to mouth ulcers. Clinical improvement and pain relief was reported in 86.6% of patients following topical, intralesional, or systemic corticosteroid therapy, with side effects limited to secondary candidiasis (n = 2). Mouth ulcers are a common and potentially dose limiting toxicity associated with the use of mTOR inhibitors in cancer treatment. This case series demonstrates that local and systemic corticosteroid therapy is an effective approach to managing patients with symptomatic mIAS. Prospective studies are necessary to evaluate the effectiveness of treatment and prevention strategies with the ultimate goal of improving overall cancer treatment outcomes.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Oral Oncology - Volume 47, Issue 10, October 2011, Pages 998–1003
نویسندگان
, , , , , , , ,